Clinical Trial Update: BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial of BAY88-8223 (Alpharadin) in breast cancer patients with bone-dominant disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer

Drugs mentioned

• Alpharadin (BAY88-8223) (BAY88-8223)

Snippet

Sponsor: Bayer | Conditions: Breast Cancer, Bone Metastases | Phase 2 | Status: COMPLETED